Patent · US Active

Therapeutic method

US9102721B2 · kind B2 · utility

1Cited by

5References

3Claims

0Family size

Assignee

FibroGen, Inc. · US

Inventors

Thomas B. Neff · Atherton, US
Seth Porter · Redwood City, US
Frank H. Valone · Mill Valley, US

Key dates

Filing date	Jan 23, 2012
Grant date	Aug 11, 2015
Priority date	—
Expiry date	Jan 23, 2032

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/505
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein are methods for treating connective tissue growth factor (CTGF)-associated cancers, including pancreatic cancer, using an anti-CTGF antibody. Increased antibody exposure was demonstrated to improve patient outcome.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.